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This research study is focused on the syntheses of radiotracers for use in 
positron emission tomography [PET] via fluorodenitration and 
fluorodehalogenation under microfluidic conditions.  Methodology has been 
developed for radiolabeling via fluorodenitration under microfluidic conditions and 
comparisons made to dehalogenation reactions.  Developmental work was 
carried out on commercially available compounds containing a variety of 
functional groups.  Subsequent production of radiotracers has been performed 
with precursors provided by collaborators as well as those synthesized in our 
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CHAPTER I  
POSITRON EMISSION TOMOGRAPHY, RADIOCHEMISTRY, 
MICROFLUIDIC REACTORS, AND FLUORINATION REACTIONS 
 
Introduction 
 This research work combines traditional organic chemistry with 
microfluidics and radiochemistry.  Developmental work was carried out on known 
compounds to test the feasibility of radiolabeling via fluorodenitration and 
fluorodehalogenation under microfluidic conditions.  Subsequently, two known 
and one novel radiotracers were prepared using this methodology.   
Radiochemistry 
PET 
Positron emission tomography (PET) has proven to be a useful tool for 
diagnosing a variety of medical conditions.  Of prime importance to successful 
PET imaging are rapid synthesis (due to the short half-lives of medically useful 
isotopes) and efficient purification of appropriate radiotracers containing sufficient 
levels of radioactivity to permit tomographic imaging.  PET is an imaging 
technique which constructs a three-dimensional image by detecting the decay of 
positron emitting isotopes.  Positron decays are not directly measured, but 
detected through the gamma rays emitted when positrons and electrons 
annihilate each other.  Positrons decay by mutual annihilation with electrons.  
This process results in the creation of a pair gamma rays, each with an energy of 
511 keV.  These gamma rays have opposite vectors, moving along a straight line 
in opposite directions.  This property is the basis for detection in PET, in which a 
ring of detectors measure the gamma ray pairs.  The point of origin of the gamma 
rays, the location of the radiotracer, can then be extrapolated.  A three-
dimensional image can then be constructed from this data.  The positron-electron 
pair can upon annihilation create greater numbers of gamma emissions based on 
its initial energy, however these are rare processes compared with the two 
gamma emission.   
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A typical PET radiotracer is an organic molecule with biological activity 
that has been modified to incorporate a positron-emitting isotope.  PET tracers 
can be relatively small molecules but can be as large as peptides.  A number of 
positron-emitting isotopes are known in the literature such as carbon-11 (t1/2= 
20.3 min), nitrogen-13 (t1/2= 2.04 min), oxygen-15 (t1/2=9.9 min), and fluorine-18 
(t1/2= 109.7 min), among others.  Due to their relatively short half lives, PET 
radiotracers require well optimized preparation procedures.  Fluorine-18 is of 
great interest to PET researchers due to its comparatively long half-life. 
Radiofluorine History 
Fluorine-19 has a natural abundance of 100%.  The positron emitting 
isotope fluorine-18 was discovered in 1937.[1]  The nucleus of fluorine-18 
contains 9 protons and 9 neutrons and decays primarily by positron decay.  Its 
109.7 minute half-life is sufficiently long for use as a radiotracer, but short 
enough that it minimizes danger to researchers and patients.  The high reactivity 
of fluorine as a halogen, its high electronegativity, and its tendency to form 
polarized bonds create difficulties in adding fluorine into organic molecules.  
These difficulties are compounded by the limited sources of 18F: aqueous 18F- or 
low specific activity [18F] F2 gas.    
Fluorine-18 can be produced via several different methods although 
cyclotron bombardment is currently favored.  Two common methods for 
producing fluorine-18 in a cyclotron result in carrier-added and no-carrier-added 
products.[2]  The former is produced by deuteron bombardment of neon-20 and 
results in fluorine gas containing the desired isotope; this is called carrier-added 
because it must necessarily contain fluorine-19 to incorporate the isotope as 
gaseous fluorine.  The latter, no-carrier-added isotope, is generated by proton 
bombardment of oxygen-18 water, leaving ionic fluorine-18 in solution.  Oxygen-
18 is a stable isotope of oxygen, found in 0.2% abundance in nature.  Fluorine-18 
decays by positron emission, a positron being a positively charged electron, to 




Figure 1. Generation of fluorine-18 by proton bombardment and decay by positron 
emission. 
 
Other methods of generating 18F include bombardment of neon-20 with 
deuterons or capturing 18F produced from oxygen-18, then reirradiating in the 
presence of F2 gas.  These methods lead to low specific activity due to the 
presence of F-19.  High specific activity [18F]F2 can be generated from aqueous 
18F- but requires additional steps after irradiation.  Specific activity is calculated 
by dividing the activity of the radioactive isotope by the concentration of all 
isotopes of the same element present.  High specific activity is desirable to avoid 
high chemical doses of the radiotracer that might affect the condition being 
examined in the PET scan.  Specific activity of radiotracers is determined before 
injection generally by radio-HPLC.  The [18F] fluorine in this work was obtained by 
proton bombardment of 18O water, generating 18F as HF, “no-carrier-added.”   
Radiochemistry 
The different types of radiofluorine have different applications.  Carrier-
added [18F]F2 can be used in electrophilic substitutions, although this provides 
low selectivity and low specific activity.  No-carrier-added fluorine-18 can be used 
for nucleophilic substitution reactions.  Although fluorine gas is highly reactive, 
fluoride ions are not.  Therefore, the incorporation of fluoride ions into molecules 
presents certain challenges.  First, the fluoride must be made sufficiently reactive 
to form a chemical bond.  This can be achieved in polar, aprotic solvents using 
chelating agents to sequester the counter ion, or by employing 
tetraalkylammonium salts, resulting in a “naked,” more nucleophilic, fluoride ion.   
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Nucleophilic fluoride substitutions can be performed on aromatic or aliphatic 
moieties.  These studies employ nucleophilic aromatic substitution, utilizing 
halide or nitro leaving groups, although quaternary ammonium leaving groups 
are also known.   
Nucleophilic substitutions using fluoride require an azeotropic drying step 
to remove water.  The presence of water decreases the reactivity of fluoride due 
to its ability to form hydrogen bonds with the fluoride ion.  First, the fluoride 
solution is passed through an ion exchange resin to separate the majority of the 
water from the fluoride.  Following this trapping step, the fluoride is eluted from 
the trap and is then subjected to azeotropic distillation with acetonitrile to remove 
remaining water. 
   
Figure 2. Structures of two commonly used radiofluoride sources. 
 
This results in a non-hydrated, “naked,” fluoride ion soluble in organic solvents.  
These trapping and drying steps can be performed automatically by the 
concentrator module of the NanoTek system.  Fluoride eluents utilizing Kryptofix 
2.2.2 also contain potassium carbonate to prevent formation of H[18F]F, a source 
of activity loss.  Potassium oxalate can be substituted for the carbonate if the 
precursor compound is base-sensitive.  However, due to toxicity of Kryptofix 
2.2.2, quaternary ammonium compounds are desirable.  Tetraethylammonium 





Fluorodenitration has developed many uses in the pharmaceutical, 
agrochemical, and dye industries since it was first observed in 1956.[3]  
Fluorodenitration, the displacement of a nitro group from an arene to yield a 
radiolabeled fluoroarene, proceeds via a Meisenheimer complex.  Electron 
withdrawing groups at the ortho- and para- positions are known to increase 
reactivity.  Aliphatic reactions require halide or sulfonic acid leaving groups.   
 
 
Scheme 1. Typical fluorodenitration reaction on a nitroarene. 
 
Scheme 2. Typical fluorodenitration mechanism. 
The reaction is often used as a substitute for dehalogenation reactions due to the 
milder reaction conditions required and the fact that it can be conducted in a 
variety of solvents.[4] These qualities, in addition to low cost, make 
fluorodenitration a desirable method for introduction of F-18 to tracers or 
prosthetic groups.  Radiolabeling using fluorodenitration has been in 
development since the 1980s;[5] it is used as an alternative to displacements 
involving aryl trialkylammonium salts and aryl halides.   Fluorodenitration is 
preferable to related trialkylammonium displacement reactions in cases when the 
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nitroprecursor is commercially available and has greater stability[6] than the 
trialkylammonium precursor.   
The term radiochemical yield can be construed to mean different things, 
ranging from the crude product yield to the purified product yield.  No matter how 
radiochemical yield is used, it refers to the percentage of isotope that is added to 
the molecule relative to the initial amount of activity available.  Here, the term 
incorporation yield will be used for crude yields determined by radio-TLC, with 
the term radiochemical yield reserved for final purified tracers.  Generally, 
radiotracers are purified via semipreparative HPLC followed by a Sep-Pak® 
purification to remove organic solvent and then elution with a biologically suitable 
solvent, i.e. ethanol or water.   
 
Microfluidic Reactors 
    
Microfluidics, which refers to the behavior of liquids on a microliter scale, 
was developed thirty years ago and one of its earliest uses was in ink jet printer 
technology, though microfluidic applications are now found in organic, inorganic, 
analytical, polymer chemistries, catalysis, and nanomaterials.  The behavior of 
liquids in the microfluidic domain is very different from that in a macroscopic 
environment and is governed by surface tension, laminar flow, thermal transfer, 
and diffusion.[7] These factors often allow for more efficient chemical reactions 
when compared to traditional vial chemistry.[8]  Stanford University and IBM 
began development of microfluidic technologies in 1977 for use in gas 
chromatography and ink jet printers, respectively.  In the last 36 years, a variety 
of microfluidic devices have been developed, including miniature valves, pumps, 
and various sensors.[9]  These devices are often created by etching glass and 
modifying the surface as desired.  Printers employing microfluidic technology 
benefit from lack of moving parts, with ink movement controlled by electric 
current or heating.  Experimental fuel injectors have also been designed using 
the same principle.  Microfluidic devices analogous to transistors and oscillators 
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may also find use in electronic-free logic devices.  Microfluidic devices for the 
separation and counting of particles have been developed in biological fields.  In 
the chemical field, microfluidics is finding utility for reactions that require extreme 
conditions as well as catalytic reactions and for screening to discover reaction 
conditions.   
Advantages 
Due to differences in results obtained when reactions are performed in 
macroscale versus microscale, chemistry conducted in microfluidic environments 
often provides benefits over vial chemistry.  Several types of microfluidic reactors 
have been developed to take advantage of the increased yields and lower 
processing times. This is especially advantageous in the syntheses of 
radiotracers.  Microfluidic reactors are commonly flow reactors, in which the 
reaction is continuous while only a small volume reacts at a given time.  Flow 
reactors allow exact control over reaction conditions and their efficiency benefits 
radiochemical reactions which employ short lived isotopes such as fluorine-18 
(t½=109.7 min); they are inherently scalable by extension of processing time.  
Microfluidic flow reactors are useful for both the development of and the 
production of radiotracers.  Reaction conditions can be quickly optimized and 
subsequently scaled up to evaluate potential radiotracers.  F-18 labeling has 
previously been carried out in both prototype[10] and commercially available 
microfluidic devices on a wide variety of precursors.  Routine production of 
commonly used radiotracers like [18F]fluorodeoxyglucose are performed using 
microfluidic  devices.[11]   
Compared with chemical reactions carried out in vials, microfluidic 
reactions provide a number of advantages.  Buildup of hazardous byproducts is 
minimized due to the flow through the smaller reactors, and even thermal 
distribution. Reactions that on larger scale might be dangerous can often be 
attempted since only a small fraction of the reagents are reacting at a given time.   
Due to their small diameter, microfluidic channels exhibit laminar flow of 
liquids and gases, meaning there is no turbulence.  The only mixing is from 
 
 8 
diffusion across the fluid stream.  Decreasing the size of a channel can lead to 
increases in rate constants of a reaction by forcing molecules into close proximity 
to each other.[12]  This decreases both reaction time and reagent volumes 
required for chemical reactions.   
Advantages derived from micro-reactors include reduced amounts of 
radioactivity and quantities of precursor molecules required for synthesis and 
ease in analysis.  Microfluidic radiochemistry has been performed for both 11C 
and 18F labeling as well as production of tracers such as [18F]fluorodeoxyglucose 
and [18F]fallypride.   
 
Experimental and Commercial Models 
Microfluidics have been used in miniaturization of chemical reactions.   
Microfluidic reactors often consist of a network of channels on a glass plate or a 
coiled loop 10-300 µm in diameter and include various support systems for ready 
storage of reagents controlled by a computer for easy control of reaction 
conditions.  Microreactors are useful in radiochemistry due to decreased 
amounts of radioisotope and precursor required as well as lower radiation 
exposure to personnel.  To date, numerous radiochemical studies have been 
conducted employing microfluidic reactors.  Many have been conducted in cases 
when properties of the product molecule lead to decomposition under thermal 
conditions.   
The NanoTek System 
The work presented here has been performed using a commercially 
available coiled-tube micro-reactor (NanoTek; Advion).  Initial studies were 
performed to determine optimum reaction conditions by varying the reaction 
temperature, flow rate, and ratio of precursor solution to fluoride solution.  The 
optimum temperature for a set of standard conditions was established through a 
series of experiments across a range of 120-220 °C.  The radiosyntheses used 
4-10 mg of precursor and the reaction times were less than 5 minutes.  After 
establishing optimum temperature, other reaction conditions were varied to 
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determine the best possible incorporation yield.  Due to the small amounts of 
products produced, rapid purification was accomplished using analytical HPLC.   
The reactions were conducted as follows:  solutions from both the [18F]fluoride 
and precursor storage loops were dispensed to a T-junction at the inlet of the 
microfluidic reactor tube.  Then, solvent, in a volume exceeding that of the 
reactor and associated tubing, was pushed behind the reactant solutions.  The 
products were collected in plastic sample vials for analysis.  Due to the rapid 
reaction times, subsequent reactions utilizing different conditions could be 
conducted easily.  Reactor clogging issues are known, but generally only occur 
due to decomposition of the kryptand or precipitation of associated salts at low 
flow rates or high temperatures.  All reactions in this study have been conducted 
with a 2 m reactor. Longer reactors could lead to increased incorporation of the 
isotope.  Scale up can be accomplished by increasing the volume of solution 
dispensed; comparable yields are achieved due to the nature of flow chemistry.   
Cyclotron-produced  no-carrier-added [18F]fluoride was separated from [18O]water 
by trapping on a MP-1 or QMA anion exchange resin cartridge followed by 
elution with a Kryptofix 2.2.2 or tetraethylammonium bicarbonate solution.  
Remaining water was removed by azeotropic distillation with acetonitrile before 
addition of anhydrous solvent.   
Radiosynthesis was performed in the NanoTek reactor module housed in 
lead shielding.  Initial radioactivity was measured using a dose calibrator in a 
separate hot cell, however. Products were analyzed on analytical HPLC at 654 




Figure 3.  Base, reactor, and concentrator modules of the NanoTek system. 
 
The NanoTek reactor system is composed of a concentrator module and micro-
reactor base module. Each module contains syringe pumps used to transport 
reagents, and heater controls.  The microreactor employed consists of coiled 
silica glass tubing.  This delicate tube is encased within a brass cartridge and a 
silicone plug to prevent damage and facilitate mounting it to the system.  Four 
reactor slots are available in the reactor module, but for this study only one 
reactor was employed.  Multiple reactors in series can also be used and 
multistep reactions at different temperatures are possible.  There is a pressure 
cut off, set at 400 psi, to avoid ruptures of the reactor.  Prior to conducting a 
study, the reactor system (including all storage loops and syringes) is cleaned 
with dry acetonitrile.  Reactions are performed by passing reagents through the 
computer controlled distribution valves to the reactor followed by sweeping the 








Figure 5. The coiled-tube reactor cartridge. 
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System set up involves filling the acetonitrile reservoir and then connecting vials 
of reaction solvent, precursor dissolved in the reaction solvent, and no-carrier-
added [18F]fluoride in [18O]water solution.  The fluoride is then trapped, eluted, 
dried, dissolved in the reaction solvent, and loaded into its storage loop.  The 
precursor solution is also loaded into its storage loop.  Optimization studies were 
then conducted.   
 
 





A nonstandard configuration was tested, with the fluoride pump volume 
increased from 1 to 2.5 mL.  This proved useful in optimization studies by 
eliminating the need to refill it, which required repressurizing the tubing system, 
but required writing a new macro taking into account its larger volume.  Analyses 
were conducted on reaction mixture and sweep solvent by injecting eluents into 
an analytical HPLC using a suitable stationary phase and solvent system.  The 
product was verified by coinjection with an authentic sample.  The overall 
radiosynthesis time (including fluoride ion drying, preheating reactor, and 




Figure 7.  User interface for the NanoTek system. 
 
 
Goal of the Project 
  
Methods for Radiolabeling via Fluorodenitration and Fluorodehalogenation 
 The goal of this project was to adapt microfluidic labeling techniques to 
fluorodenitration chemistry.  A library of nitro aryl compounds was investigated to 
determine the suitability of the NanoTek system to fluorodenitration chemistry.  
Once these compounds were successfully radiolabeled, known radiotracers 
could be synthesized using this methodology.  These tracers included small 
molecules and prosthetic groups for labeling peptides.  Finally, a complete 










CHAPTER II  
PRELIMINARY INVESTIGATION OF MICROFLUIDIC 
FLUORODENITRATION 
 
Microfluidic radiofluorodenitrations have been successfully performed 
using a commercially available microfluidic reactor system.  Reactions of 
nitroarenes with para-substituted, electron withdrawing groups provided 
incorporation yields ranging from 43-97%.  Ortho- and meta-substituted 
nitroarenes provided incorporation yields up to 35%.  The reactions were 
conducted using dry, no-carrier-added [18F]-fluoride and K2CO3/K222 dissolved in 
N,N-dimethylformamide or dimethyl sulfoxide with total synthesis times of less 
than five minutes.  The methodology developed in these studies can be applied 
to the synthesis of a variety of fluorine-18 labeled radiotracers and radiolabeled 




The application of microfluidic syntheses to fluorodenitration has the 
benefit of being rapid and high yielding under the conditions shown in Scheme 3.  
Using similar conditions in a vial, even with microwave assistance, generally 
results in relatively poor to modest yields[14] while requiring longer reaction times.  
The ease in optimization of the reaction conditions in microfluidic devices, 
coupled with the variety of nitroarene precursors available from numerous 
sources, presents an opportunity for more efficient production of known and new 
radiopharmaceuticals.  In this study, we examined fluorodenitration in microfluidic 
reactors on small molecules that were either precursors to known tracers and 
prosthetic groups, or functioned as models for potential tracers.  This 
methodology can be applied to improve synthesis of known and new 







Microreactor (100 µm x 2 m)







Scheme 3. Typical radiofluorodenitration conditions for aryl groups bearing ortho, meta, 
and para electron withdrawing groups. 
Results and Discussion 
 
The nitroarenes (Table 1) were dissolved in an appropriate anhydrous 
solvent (dimethyl sulfoxide or N,N-dimethylformamide) at nitroarene 
concentrations of  2 - 5 mg per 0.5 mL of solvent.  The nitroarene and [18F]F- 
solutions (prepared separately) were then passed through the microfluidic reactor 
(100 μm x 2 m).  Radiolabeling conditions were optimized (Tables 2 and 3) by 
adjusting reaction temperature, flow rate, and the ratio of precursor to fluoride 
solutions in the Discovery Mode of the NanoTek system.  After loading the 
precursor solution and the fluoride solution, optimum reaction conditions were 
obtained by varying temperature, flow rate, and the volume ratio of fluoride 
solution to precursor solution.   
The initial reaction temperature was 120 °C which was increased in 
increments of 20 °C for each subsequent experiment; a flow rate of 30 μL/min 
was used along with a reagent ratio of 1:1 fluoride solution:precursor solution.  
Upon passing through the reactor, aliquots of the reaction mixture were spotted 
on to thin layer chromatography plates and developed using ethyl acetate.  The 
most efficient set of reaction conditions are reported in Table 1.  Typical reactor 
runs were approximately 5 minutes, but varied slightly with flow rate.  Processing 
time can be calculated by dividing the aliquot size (10 or 20 μL) by the total flow 
rate through the reactor.  The flow rates listed in Table 2 refer to the flow rate of 
the isotope solution (P3) and the flow rate of the precursor solution (P1) in 
µL/min. The upper temperature limit for these studies was 210 °C due to clogging 
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related to salt precipitation at higher temperatures.  Isotope incorporation yields 
were determined by radio-TLC.  The identities of the products were confirmed 
using analytical HPLC by co-injection with authentic samples.   
Solvent effects were observed in preliminary studies employing ethyl 4-
nitrobenzoate and ethyl 3-nitrobenzoate. Yields varied with solvents, DMF 
provided somewhat better yields than DMSO for the majority of compounds 
evaluated, which is in agreement with other fluorodenitration studies using these 
solvents.[15]  A solvent mixture of DMF/DMSO was also evaluated with the 
precursor dissolved in DMSO and the fluoride dissolved in DMF.   Results in 
DMF/DMSO mixtures were similar to those obtained in DMF at low ratios of 
precursor to fluoride but resembled yields in DMSO at high precursor to fluoride. 
Several trends in the reactivity of ortho, meta, and para nitroarenes emerged.  
Para substituted nitroarenes were found to provide excellent yields of 
radiolabeled product.  Meta substituted nitroarenes gave generally poor results.  
Ortho substituted nitroarenes were found to be somewhat efficient.  Ethyl 2-
nitrobenzoate and 2-nitrobenzaldehyde were briefly examined but were found to 
clog the microreactor under the conditions used. 
An attempt was made at correlating the electron-withdrawing ability of the 
aryl ring substituents with the optimized incorporation yields of the compounds.  
Both σ and σ- values were used in this comparison.  Although these results 
affirmed the relationship of greater electron-withdrawing ability with increased 











Table 1. Precursor concentration, TLC Rf value, HPLC retention time and incorporation 
yields in both DMF and DMSO solvents. 
 










ethyl 4-nitrobenzoate 4 mg/mL (21 mM) 85 51 0.69 10.2 
4-nitrobenzaldehydeb 5 mg/mL (33 mM) 53 68 0.66 5.1 
4’-nitroacetophenone 10 mg/mL (61 
mM) 
94 64 0.66 5.6 
4-nitrobenzophenone 10 mg/mL (44 
mM) 
87 43 0.70 11.8 
4-nitrobenzonitrile 4 mg/mL (27 mM) 89 81 0.68 5.7 
1,4-dinitrobenzene 4 mg/mL (24 mM) 97 66 0.70 6.7 
ethyl 3-nitrobenzoate 4 mg/mL (21 mM) 7 2 0.67 10.5 
3-nitrobenzaldehydeb 5 mg/mL (33 mM) 1 9 0.66 5.6 
6-nitropiperonal 5 mg/mL (26 mM) 28 35 0.63 5.2 
6-nitroveratraldehyde 5 mg/mL (24 mM) 32 15 0.61 4.8 
3-methoxy-2-
nitropyridine 
4 mg/mL (26 mM) 74 88  0.56 -c 
ethyl 4-nitrobenzoatea 10 mg/mL (53 
mM) 
81 81 0.69 10.2 
ethyl 3-nitrobenzoatea 4 mg/mL (21 mM) 14 14 0.67 10.5 
aAdditional reactions conducted using [18F]F- dissolved in DMF and precursor 
dissolved in DMSO.   
bYields for 3- and 4-fluorobenzaldehyde were obtained by trapping with 2,4-
dinitrophenylhydrazine solution.   
















ethyl 4-nitrobenzoate 4 mg/mL 200 20 20 
4-nitrobenzaldehyde 5 mg/mL 210 30 30 
4’-nitroacetophenone 10 mg/mL 200 20 20 
4-nitrobenzophenone 10 mg/mL 200 10 20 
4-nitrobenzonitrile 4 mg/mL 200 20 20 
1,4-dinitrobenzene 4 mg/mL 180 30 30 
ethyl 3-nitrobenzoate 4 mg/mL 160 20 20 
3-nitrobenzaldehyde 5 mg/mL 210 20 20 
6-nitropiperonal 5 mg/mL 160 10 30 
6-nitroveratraldehyde 5 mg/mL 210 10 30 
3-methoxy-2-nitropyridine 4 mg/mL 200 10 20 
ethyl 4-nitrobenzoatea 10 mg/mL 200 20 10 
ethyl 3-nitrobenzoatea 4 mg/mL 200 30 30 
aAdditional reactions conducted using [18F]fluoride dissolved in DMF and 
























ethyl 4-nitrobenzoate 4 mg/mL 200 10 10 
4-nitrobenzaldehyde 5 mg/mL 180 20 20 
4’-nitroacetophenone 10 mg/mL 200 30 30 
4-nitrobenzophenone 10 mg/mL 210 10 10 
4-nitrobenzonitrile 4 mg/mL 180 10 10 
1,4-dinitrobenzene 4 mg/mL 140 30 30 
ethyl 3-nitrobenzoate 4 mg/mL 140 20 20 
3-nitrobenzaldehyde 5 mg/mL 180 20 40 
6-nitropiperonal 5 mg/mL 200 20 20 
6-nitroveratraldehyde 5 mg/mL 210 30 90 
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Materials and Methods 
All precursors, standards and solvents were purchased from Acros, 
Aldrich, Alfa Aesar, or Matrix Scientific and were used as received. 6-
Fluoropiperonal was prepared according to the reported procedure[16].  No-
carrier-added [18F]F-, (740-1110 MBq, specific activity >74 GBq/µmole) produced 
from recycled [18O] water, was obtained from PETNet (Knoxville, TN).  Thin-layer 
chromatography visualization was performed with radiation detectors using a 
BioScan AR-2500 radio-TLC reader and WinScan1.3 software.  All TLC plates 
were developed using ethyl acetate as eluent. Volatile aldehydes were trapped 
as 2,4-dinitrophenylhydrazone derivatives for TLC analysis.  Analytical radio-
HPLC analyses were performed on an Agilent 1200 series instrument employing 
a 254 nm UV detector and a Phenomenex Luna C18 column, 5 μ, 4.6 x 250 mm, 
using acetonitrile:water (70/30) as eluent  and a flow rate of 1 mL/min.  F-18 
labeling was performed in 100 μm x 2 m reactors in the Discovery Mode of the 
Advion NanoTek Microfluidic Synthesis System controlled by NanoTek LF 1.4 
Software.  Products were collected in sample vials for analysis upon exit from the 
reactor.   
The water concentration in the anhydrous DMF and DMSO in these 
studies is <0.005% and <50 ppm respectively and are assumed to be “dry,” with 
a maximum water concentration of 3 mM.  For 49.0 mCi of fluorine-18 at a 
specific activity of 74 GBq/µmol dissolved in 0.5 mL of solvent, the fluoride 
concentration is approximately 50 µM.  The precursor molecule concentrations 
ranged between 21 and 61 mM prior to mixing in the reactor.  Excess amounts of 
water inhibit fluorination reactions, but a total lack of water can lead to side 
reactions with reagents or solvent due to the basicity of anhydrous fluoride.[4]  
Although there is an excess of water relative to fluoride in these solutions, 
fluoride is known to be nucleophilic as the tetrahydrate,[17] even in the presence 
of trace water beyond the tetrahydrate.[18] 
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General procedure for preparation of [18F]fluoroarenes (2) 
The nitro precursor (1) was placed in a 1 mL tapered bottom vial and sealed with 
a septum.  Solvent was added to create a solution of the concentration indicated 
in Table 1.  [18F]F- was converted to K[18F]F-Kryptofix222 in the NanoTek System 
concentrator module. The [18F]F- solution and the precursor solution were then 
passed through the microfluidic reactor at various temperatures and flow rates.  
Optimum reaction temperatures, ratios of precursor to fluoride solutions, and flow 
rates were found to be 190±10 °C, 1:1 or 2:1, and 40-60 μL/min respectively.  
Reaction mixtures were then spotted onto aluminum-backed silica TLC plates 
and developed in ethyl acetate.  Radio-TLC provided radioisotope incorporation 
yields and co-injection with authentic samples on radio-HPLC confirmed the 
product identity (2). 
The Microfluidic Reactor 
The microfluidic reactor system used in this study is composed of a concentrator 
and reactor module and a base module.  The NanoTek system was placed in a 
fume hood, with the concentrator and reactor modules contained within lead 
shielding.  The operation of the modules is conducted via computer software 
controls, which monitors the cleaning, fluoride drying, reagent loading, reaction, 
and sweep stages after several manual inputs.  Both prior to (and after) daily 
experiments, the system was cleaned using dry acetonitrile.  Vials of reagent 
solutions and pure solvent were then connected to tubing leading to their 
respective modules.  After drying of the fluoride using standard protocols 
(sequential addition/evaporation of anhydrous acetonitrile) and loading of 
reagents into the system, 15-30 reactions were performed to optimize reaction 
conditions.  The configuration and the operation of the NanoTek LF system have 






A radiofluorodenitration study of nitroarenes has been conducted.  The 
effects of solvents and concentration on fluorodenitration reactions have been 
investigated. N,N-Dimethylformamide was found to be the solvent of choice for 
most compounds tested. Optimum reaction temperatures were in the range of 
180-200 ˚C with over all flow rates of 40-60 µL/min.  The results indicate that 
fluorodenitration can be efficiently achieved using a commercial microfluidic 


































RADIOLABELING FPEB VIA MICROFLUIDIC REACTORS 
 
Introduction 
 The Nanotek microfluidic system was used to synthesize the mGLUR5 
receptor imaging agent [18F]FPEB.  To study the effect of solvents and counter 
ions on the synthesis of the desired compound, the chloro-, bromo-, iodo-, and 
nitro-substituted precursors for FPEB were evaluated.  Precursor concentrations 
of 4-10 mg/mL were evaluated in various solvents, with temperature ranges 
between 120 to 220 °C and total processing times of less than five minutes.  
Optimized incorporation yields ranged from 5% to 70% depending on the 
precursor used.   
Previous experiments have demonstrated the utility of microfluidic devices in the 
rapid (processing time under five minutes) and high yielding (incorporation yields 
up to 95%) syntheses of a number of PET radiotracers from nitro-precursors 
using no-carrier-added [18F]KF.  Scheme 4 contains an outline of the nucleophilic 
aromatic substitution reaction used in this study.  Although substitution of 
electron withdrawing groups in the para position led to the most efficient 
radiolabeling under microfluidic conditions, several compounds provided 
evidence for improved labeling of meta-substituted compounds.[19]  These 
preliminary studies also demonstrate that nitro-displacements are more efficient 
than iodo-displacements.  4-Nitrobenzonitrile and 4-iodobenzonitrile were labeled 
utilizing the NanoTek system, providing yields of 89% and 31% respectively.   
 
Scheme 4. Typical conditions for nucleophilic aromatic substitution reaction using various 
FPEB precursors.  
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 3-[18F]Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB) has been 
shown to be a high affinity binding agent to the metabotropic glutamate receptor 
5 (mGluR5).  Autoradiography studies have shown a regional distribution with the 
highest binding sites density in the cortex, striatum, and hippocampus, moderate 
in the thalamus and the lowest in the cerebellum  of three mammalian species[20].  
Recent studies have shown that [18F]FPEB could be a useful PET imaging agent 
for in vivo evaluation of neurological conditions involving defects in metabotropic 
glutamate receptors, including pain and addiction diseases as well as 
neurodegenerative diseases.[21]  Vial synthesis under microwave conditions and 
subsequent purification of [18F]FPEB generally requires up to 2 hours with a 




F]FPEB and glutamate. 
 
Results and Discussion 
The FPEB precursor (Cl, Br, I, or NO2) was dissolved in anhydrous DMSO 
or DMF, at a concentration of 4-10 mg/mL.  [18F]Fluoride solution was prepared 
using the concentrator module of the NanoTek system.  Potassium carbonate - 
Kryptofix K222 or tetraethylammonium bicarbonate was used to elute the fluoride 
from the MP-1 or QMA fluoride trap and then the fluoride solution prior to the 
azeotropic drying step and dilution with the solvent used to dissolve the FPEB 
precursor.  Both precursor and the fluoride solutions were then loaded on to 
storage loops and passed through the microfluidic reactor (100 µm x 2 m) using 
the Discovery mode of the NanoTek system.  Initial experiments were started at 
a temperature of  140 °C and then increased in 20 degree increments using an 
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initial fluoride solution (pump 3; “P3”) flow rate of 30 µL/min and ratio of precursor 
(pump 1; “P1”) to fluoride (P3) = 1:1. This resulted in a combined flow rate 
through the microfluidic reactor of 60 µL/min. The latter two variables (P3 flow 
rate and P1: P3 ratio) were then adjusted using the temperature found to 
generate the highest yield among the initial experiments until optimized reaction 
conditions were attained.  Incorporation yields (crude radiochemical yields) were 
determined by radio-TLC.  Product identity was confirmed by co-injection with an 
authentic sample, using an analytical HPLC equipped with dual gamma and UV 
detector.    
Experiments employing FPEB precursor at 4 mg/mL showed the order of 
reactivity of the precursors to be NO2>Cl>Br>I.  Results from these experiments 
are presented in Figures 9 through 12.  Neither DMSO nor DMF provided any 
notable solvent effect on the radiochemical yields.  Fluoride eluent composition 
[standard potassium carbonate-K222, Hamill K222 (Kryptofix/bicarbonate/oxalate 
mixture), potassium oxalate-K222, or tetraethyammonium bicarbonate] had no 
significant effect on radiochemical yields.  Optimized conditions for the 4 mg/mL 
precursor series of reactions ranged between 200-210 °C with P3 flow rates 
between 5-30 µL/min and ratios of precursor solution to fluoride solution between 
1:1 and 3:1.   
Reactions using a precursor concentration of 10 mg/mL were then 
performed to ascertain whether increasing the amount of precursor would 
increase incorporation yield.  For Cl, Br, and I, the results are presented in Figure 
9, Figure 10, and Figure 11; for nitro, refer to Figure 12 and Figure 13.  These 
higher concentration reactions employed tetraethylammonium bicarbonate as the 
base to decrease the likelihood of clogging the microfluidic reactors at high 
temperatures and low flow rates.  At 10 mg/mL of precursor, the order of 
reactivity was found to be NO2>Br>Cl>I.  Optimized reaction conditions at the 10 
mg/mL precursor concentration ranged from 200-220 °C, with P3 flow rates of 5-
10 µL/min, and precursor to fluoride ratios of 1:1 or 2:1.  The optimized 




Figure 9.  Reactions using the chloro-precursor at 4 and 10 mg/mL, in DMF and DMSO with 
various eluents. 
 

















1 4 DMF K222/K2CO3 210 20 1 16.1 
2 4 DMSO K222/K2CO3 200 20 3 7.3 
3 10 DMSO K222/K2CO3/ 
oxalate 
210 5 1 25.8 













































Figure 10. Reactions using the bromo-precursor at 4 and 10 mg/mL, in DMF and DMSO 
with various eluents. 
 

















1 4 DMSO K222/K2CO3 200 30 1 6.8 
2 4 DMSO K222/K2CO3 210 5 2 13.4 
3 4 DMF K222/K2CO3 210 30 1 10.6 






































Figure 11.  Reactions using the iodo-precursor at 4 and 10 mg/mL in DMF and DMSO with 
various eluents. 
 

















1 4 DMSO K222 210 5 3 12.5 
2 4 DMSO K222/K2CO3 200 10 1 3.7 
3 4 DMF K222/K2CO3 200 30 1 11.6 
4 4 DMF K222/K2CO3 200 20 2 12.7 




































Figure 12.  Reactions using the nitro-precursor at 4 mg/mL in DMF and DMSO with various 
eluents. 
 

















1 4 DMSO K222/K2CO3 160 30 3 35.2 
2 4 DMSO K222/ 
oxalate 
210 30 1 8.5 
3 4 DMSO K222/K2CO3 210 15 2 24.6 
4 4 DMF K222/K2CO3 200 5 2 41.6 
5 4 DMF K222/K2CO3 200 5 2 52.3 
6 5 DMSO K222/ 
oxalate 




































Figure 13.  Reactions using the nitro-precursor at 10 mg/mL, in DMSO with various 
eluents. 
 

















1 10 DMSO K222/oxalate 200 5 1 32.1 
2 10 DMSO TEAB 210 10 1 46.0 
3 10 DMSO TEAB 220 5 1 65.2 
4 10 DMSO K222/K2CO3 210 5 1 69.4 




















































Table 9.  Optmized conditions irrespective of solvent at 4 mg/mL precursor concentration. 
 
 




Materials and Methods 
The FPEB precursors were provided by collaborators at the Institute for 
Neurodegenerative Disorders, New Haven, CT and used as received.  
[18F]Fluoride was made from recycled [18O] water and purchased from PETNet 
(Knoxville, TN).  Anhydrous solvents were purchased from Acros and used as 
received.  Inorganic salts were purchased from Fisher and used as received.  
Radio thin layer chromatography was performed with radiation detection using a 
BioScan AR-2500 radio-TLC reader and WinScan 1.3 software.  TLC plates were 
developed in a mixture of 9:1 chloroform:methanol.  Analytical radio-HPLC 
analyses were performed on an Agilent 1200 series instrument employing a 254 
nm UV detector and a Phenomenex phenylhexyl column, 5 µm, 4.6 x 250 mm, 
using a 60:40 mixture of acetonitrile:0.1 M ammonium formate buffer.  Fluorine-
18 labeling was performed in 100 µm x 2 m reactors using the Discovery mode of 
the Advion NanoTek Microfluidic Synthesis System controlled by NanoTek LF 1.4 
Precursor Temperature 
(°C) 
P3 flow rate 
(µL/min) 
P1 flow rate Incorporation 
Yield (%) 
Cl 210 20 20 16 
Br 210 5 10 13 
I 200 20 40 13 
NO2 200 5 10 52 
Precursor Temperature 
(°C) 
P3 flow rate 
(µL/min) 
P1 flow rate Incorporation 
Yield (%) 
Cl 210 5 5 26 
Br 220 5 10 30 
I 220 5 5 13 
NO2 210 5 5 69 
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Software.  Samples were collected in plastic, capped sample vials upon exit from 
the reactor for analysis.   
General Procedure for Preparation of [18F]FPEB 
The FPEB precursor (Cl, Br, I, or NO2) was placed in a 1 mL glass tapered 
bottom vial and sealed with a septum.  Solvent was added to create a solution of 
the desired concentration.  [18F]Fluoride was eluted from the ion exchange trap 
(standard or QMA trap) with one of the following eluents: standard 
acetonitrile/water K222/K2CO3 solution, acetonitrile/water K222/K2CO3/oxalate 
solution, acetonitrile/water K222/oxalate solution, or tetraethylammonium 
bicarbonate solution.  Optimum temperatures ranged between 200-210 °C.  
Optimum flow rates ranged from 5-30 µL/min and optimum ratios of precursor 
solution to fluoride solution ranged between 1:1 and 3:1.   
  
The Microfluidic Reactor 
The microfluidic reactor system used in this study is composed of a concentrator, 
reactor module, and a base module.  The reactor was placed in a fume hood, 
with the concentrator and reactor modules contained within lead shielding.  The 
operation of the modules is conducted via computer software controls and the 
software monitors the cleaning, fluoride drying, reagent loading, reaction, and 
sweep stages after several manual inputs.  Both prior to (and after) a daily 
experiment, the system was cleaned using dry acetonitrile.  Vials of reagent 
solutions and solvent were then connected to tubing leading to their respective 
modules.  After drying of the fluoride using standard protocols (sequential 
addition/evaporation of anhydrous acetonitrile) and loading of reagents into the 
system, 15-30 reactions were performed to optimize reaction conditions.  The 
configuration and the operation of the NanoTek LF system have been previously 




Experimental procedures developed on model radiotracers have been 
applied to the synthesis of [18F]FPEB.  [18F]FPEB was synthesized from four 
different precursors in crude incorporation yields of up to 69%.  Total reaction 
times were less than five minutes providing an advantage over current literature 
procedures.  The ability to synthesize [18F]FPEB more efficiently provides the 























CHAPTER IV  
SYNTHESIS OF NOVEL THIOL-REACTIVE PROSTHETIC GROUP 
 
Introduction 
Biomolecules are increasingly useful in diagnosis of disease due to their 
known interactions in vivo.  Diseases can be diagnosed or located by employing 
antibodies or antibody fragments that have been radiolabeled in combination with 
PET.[23]  However, labeling biomolecules such as peptides presents difficulty due 
to the quantity and diversity of functional groups present.  Direct incorporation of 
fluoride into biomolecules is impractical because it requires harsh conditions 
which may damage large peptides.[24]  In order to circumvent this difficulty, 
techniques for peptide labeling using prosthetic groups have been developed.  
Prosthetic groups are molecules designed to react with functional groups on a 
peptide rapidly under mild conditions after previously incorporating the desired 
radioactive atom.  Generally, prosthetic groups target amines or thiols present in 
the biomolecule.  Due to the variety of biomolecules scientists wish to use in their 
studies, a selection of prosthetic groups is necessary to accomplish labeling 
quickly and efficiently.  
Amine reactive prosthetic groups such as N-succinimidyl-4-
[18F]fluorobenzoate (SFB) are useful for labeling certain molecules and labeling 
under physiological conditions.  However, SFB is nonspecific and labels all free 
amines rendering it useless as an imaging agent if a free amine is critical to the 
functionality of the biomolecule.  Additionally, the reactivity of amine reactive 
prosthetic groups may be dependent on lipophilicity or steric hindrance in the 
biomolecule.[24]  The unsuitability of amine reactive prosthetic groups to certain 
peptides has generated interest in thiol reactive prosthetic groups that are 
selective.  Further, thiol-reactive prosthetic groups react rapidly and require fewer 




Figure 14.  Various thiol reactive prosthetic groups reported in literature, and FBAMPy. 
In addition to naturally occurring proteins containing cysteine residues, mutant 
proteins incorporating a single cysteine have been developed for labeling.[26]  
Numerous sulfur reactive prosthetic groups have been developed, that 
incorporate a maleimide unit which reacts with sulfur and a pendant holding the 
radioactive atom.  Fluorobenzaldehyde-O-(2-{2-[2-(pyrrol-2,5-dione-1-yl)ethoxy]-
ethoxy}-ethyl)oxime (FBOM) was found to be suited for labeling hydrophilic 
peptides under aqueous conditions.[24]  Fluorobenzaldehyde-O-[6-(2,5-dioxo-2,5-
dihydro-pyrrol-1-yl)-hexyl]oxime (FBAM) is well suited for high molecular weight 
molecules, however its lipophilicity causes it to absorb at undesired locations.[25]  
Both FBOM and FBAM have been used to label glutathione.[24]  A four carbon 
variant of FBAM, N-[4-[(4-fluorobenzylidine)aminooxy]butyl]maleimide (FBABM), 
is used for labeling Annexin V, which is used to detect apoptosis.[27]  A maleimide 
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ether with a pyridine unit, (1-[3-(2-fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione 
(FPyME), has been developed and tested on several peptides.[28]  Clearly, variety 
in prosthetic groups is desirable.  To that end, we have combined the six carbon 
chain heterobifunctional linker used in the synthesis of FBAM with a pyridine 
moiety to create a new molecule, FBAMPy, for the biochemist’s labeling tool box.   
 
Results and Discussion 
2-Bromonicotinaldehyde was allowed to react with dried [18F]fluoride in a 
microfluidic reactor or in a vial.  In either case, fluoride drying was performed 
utilizing the concentrator module of the NanoTek system before the fluoride was 
dissolved in DMF.  For microfluidic syntheses, the concentration of the precursor 
was 4 mg/mL in DMF and the optimized conditions were found to be T = 220 °C, 
flow rate = 5 µL/min, and P3:P1 ratio = 2:1; for vial syntheses, the concentration 
was also 4 mg/mL in 1 mL of DMF. Vial syntheses were performed by addition of 
fluoride and heating to 160 °C for 20 minutes.  Incorporation yields of these 
reactions were both 51 - 56%.  The microfluidic synthesis was completed by 
bubbling the solution from the reactor directly into a solution of 10 mg of the 
maleimide tail unit in 1 mL acetonitrile and 1 mL 2 N HCl, followed by heating the 
vial to 70 °C for 10-15 minutes.  The vial synthesis was completed with an 
identical solution of maleimide tail unit combined with the solution of fluorinated 
pyridine and heated using the same procedure.  On analytical HPLC, the Rf of 









Scheme 7.  Radiolabeling of 2-bromonicotinaldehyde and reaction with tail unit.  Non-
radioactive FBAMPy was produced in the same manner using 2-fluoronicotinaldehyde. 
 




Figure 15.  Incorporation yields of 2-bromonicotinaldehyde in DMF at 4 mg/mL 
concentration with total flow rate of 60 µL/min. 
 






P3 Flow Rate 
(μL/min) 




4 220 10 10 32 
4 220 30 60 53 
4 220 40 40 48 
4 220 50 50 48 
4 220 50 150 46 
4 220 30 90 47 
8 220 30 60 24 
 
Materials and Methods 
All chemicals and solvents were purchased from Aldrich and Acros and 
used as received.  2-Fluoronicotinaldehyde was prepared according to a 
literature procedure.[29]  No-carrier-added [18F]F-, (740-1110 MBq, specific activity 
>74 GBq/µmole) produced from recycled [18O]water, was obtained from PETNet 
(Knoxville, TN).  Radio thin layer chromatography was performed with radiation 























2-bromonicotinaldehyde 4 mg/mL DMF 
30 µL/min 1:1 
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TLC plates to test completeness of fluorination of 2-bromonicotinaldehyde were 
developed in ethyl acetate.  Analytical radio-HPLC analyses were performed on 
an Agilent 1200 series instrument employing a 254 nm UV detector and a 
Phenomenex C-18 column, 5 µm, 4.6 x 250 mm, using a 80:20 mixture of 
acetonitrile:0.1 M ammonium formate buffer in a standard FBAM gradient.  
Microfluidic fluorine-18 labeling was performed in 100 µm x 2 m reactors using 
the Discovery mode of the Advion NanoTek Microfluidic Synthesis System 
controlled by NanoTek LF 1.4 Software.  Samples were collected in plastic, 
capped sample vials upon exit from the reactor for analysis.  Vial labeling was 
performed in a 5 mL tapered bottom vial containing 4 mg/mL precursor in 1 mL 
DMF following the addition of the entire loop of dried fluoride in DMF. 
 
2-Fluoronicotinaldehyde 
(Trimethylsilylmethyl)lithium (34.6 mL 0.7 M solution in hexanes; 24.2 mmol) was 
added to a three necked 100 mL round bottomed flask along with a magnetic stir 
bar, under argon purge.  After cooling to -50 °C, a solution of 2-
fluoropyridine/THF/diisopropylamine (1.5 mL; 20.6 mmol/25 mL/0.13 mL; 0.93 
mmol) was added over ~1 min.  After stirring for 3 h, N-formylpiperidine (2.35 mL; 
21.2 mmol) was added.  The solution was stirred overnight, allowing solution to 
warm to room temperature, and then quenched with acetic acid/water (3 mL/7 
mL).  The aqueous layer was separated, washed with ether and the combined 
organic layers dried over anhydrous MgSO4 and the solvent removed to give 
brown oil.  The product was purified using flash chromatography (15% ethyl 
acetate/hexane) to give 0.833 g 2-fluoronicotinaldehyde (32.4%), which gave a 









Triphenyl phosphine (4.5 g; 17.15 mmol) was dissolved in THF (20 mL) prior to 
addition of diisopropyl diazene-1,2-dicarboxylate (4.16 g; 20.58 mmol) at 0 °C.  
Additional THF (15 mL) was added if a solid formed.  This solution was stirred for 
30 minutes followed by addition of tert-butyl (6-hydroxyhexyl)oxycarbamate (4 g; 
17.15 mmol) in THF (15 mL) at -20 °C.  Subsequently, maleimide (1.66 g; 17.15 
mmol) was added under an argon purge and the reaction was stirred for 16 h 
while warming to room temperature.  Purification was accomplished by flash 
chromatography, first employing a 20% ethyl acetate/hexane eluent followed by a 
second flash chromatography column with 1% methanol/methylene chloride 
eluent.  Deprotection using HCl in ethyl acetate gave the desired product.   
 
2-Fluoronicotinaldehyde O-(6-(2,5-dihydro-1H-pyrrol-1-yl)hexyl) oxime 
(FBAMPy) 
2-Fluoronicotinaldehyde (31 mg; 0.25 mmol) and 1-(6-(aminooxy)hexyl)-1H-
pyrrole-2,5-dione hydrochloride (42 mg; 0.17 mmol) were separately dissolved in 
1 mL DMF, then mixed, and stirred for 30 minutes.  This solution was then diluted 
with water to form a white, cloudy solution which was extracted with diethyl ether. 
The solution was washed with water and then concentrated to yield the product 
as a colorless oil.  This sample was used for spectroscopy and elemental 
analysis as well as an authentic sample for coinjection verification.   1H NMR 
(500 MHz, Chloroform-d) δ 8.22 – 8.10 (m, 2H), 7.14 (dddd, J = 7.4, 5.0, 1.7, 0.7 
Hz, 1H), 6.61 (s, 1H), 4.11 (t, J = 6.6 Hz, 2H), 3.45 (t, J = 7.3 Hz, 2H), 1.71 – 









General Procedure for Preparation of [18F]FBAMPy 
2-Bromonicotinaldehyde was placed in a 1 mL glass tapered bottom vial and 
sealed with a septum.  Solvent was added to create a solution of the desired 
concentration.  [18F]Fluoride was eluted from a QMA ion exchange trap with 
tetraethylammonium bicarbonate solution.  The optimum temperature obtained 
was 220 °C.  Flow rates between 10 and 50 µL/min were tested and precursor to 
fluoride ratios of 1:1 to 3:1 were tested.  The radiolabeled product was collected 
directly into a V bottomed 5 mL vial containing a solution of maleimide tail and 2 
N HCl dissolved in methanol.   
 
Conclusion 
 A novel thiol-reactive prosthetic group, FBAMPy, has been designed by 
combining attributes of the known prosthetic groups FBAM and FPyME.  
Microfluidic fluorodebromination of 2-bromonicotinaldehyde provided 
incorporation yields of 53%.  Comparable thermal yields were also obtained.  
[18F]FBAMPy is a new, potentially useful prosthetic group to improve the 






















CHAPTER V  
MICROFLUIDIC SYNTHESIS OF AMINOALKYLINDOLE 
FLUORINE-18 LABELLED CANNABINOID 
Introduction 
The CB1 cannabinoid receptor belongs to a family of proteins named G-
protein-coupled receptors[30] whose purpose is the transmission of information 
from the outside to the inside of cells.  CB1 is found throughout the mammalian 
body[30] (whereas the CB2 receptor is located in the immune system
[31]) but is 
primarily located in the brain and is key to signal transduction related to 
metabolism and the nervous system.  The activation of the CB1 receptor by an 
agonist leads to the activation through signal transduction of enzymes leading to 
changes in cellular calcium ion concentration or the activation of mitogen-
activated protein kinase enzymes[30].   The CB1 receptor is thought to have some 
level of basal activity causing some of the receptors to activate the desired 
enzymes without the presence of a ligand, although the exact cause is under 
debate. These proteins can adopt multiple conformations, regulating different 
processes, and act in absence of an agonist.  The CB1 receptor can be 
desensitized by the protein β-arrestin,[30] similarly to other G-protein-coupled 
receptors, although this is possibly dependent on agonist type.  CB1 is activated 
by hydrophobic neurotransmitters such as anandamide (“endocannabinoids”),[31] 
classical cannabinoids such as (−)-trans-Δ9-tetrahydrocannabinol (THC), the 
active ingredient in marijuana, compounds known as non-classical cannabinoids, 
defined as containing only some of the functionality of a classical cannabinoid,[32] 
as well as compounds known as non-traditional cannabinoids.  
 Following the isolation and characterization of THC (a known agonist of 
CB1) in 1964,
[33] the neurotransmitter anandamide was identified.  Anandamide is 
formed from arachidonic acid and ethanolamine in the body and when the CB1 
receptor is to be shut off, it is hydrolyzed by the fatty acid amide hydrolase 
enzyme.[34]  Thus far, therapeutic drugs to treat defects to the CB1 receptor are 
either fatty acid hydrolase inhibitors or high affinity agonists for the CB1 receptor 
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itself.  Many of the latter compounds are known as non-traditional cannabinoids 
which are members of these families: naphthoylindoles, naphthylmethylindoles, 
naphthoylpyrroles, naphthylmethylindenes, and phenylacetylindoles.[35]  The 
most common of these are the naphthoylindoles, with dozens of compounds 
known in scientific literature.  Vital features of endocannabinoids, traditional 
cannabinoids (as in THC) and non-traditional cannabinoids are a phenolic 
hydroxyl group, a hydrophobic side chain, an aliphatic hydroxyl group, and 
sometimes a second aliphatic hydroxyl group.[36]  Naphthoylindoles, such as the 
molecule studied here, retain the hydrophobic side chain in the form of the 
naphthyl group, but the function of the aromatic hydroxyl group is performed by a 
carbonyl group.  The aliphatic amine is also a potential interaction site.[37]  
Conformational studies employing similar compounds and their indene 
analogues show that aromatic stacking involving the naphthyl group is an 
important interaction.[38]  A hybrid cannabinoid incorporating an alkyl indole 
appended to a classical cannabinoid moiety, as opposed to a naphthyl group, 
has a potency similar to classical cannabinoids and less than WIN-55,212-2,[39] 
an aminoalkylindole containing a naphthyl ring.  
 




 Non-traditional cannabinoids have increasingly come to the attention of 
the public in recent years due to their presence in herbal incense mixtures or 
bath salts which can be consumed for their marijuana-like effects.[35]  Regulations 
on these compounds have increased with their greater exposure.  Drugs 
targeting cannabinoid receptors have potentially broad applications, with the 
ability to affect appetite, addiction, and nervous system disorders.  Rat studies 
have shown that introduction of CB1 agonists promotes consumption of 
carbohydrates and ethanol, and inhibition by an antagonist has the opposite 
effect.[40]  Radiolabelled cannabinoids have been utilized in studies of healthy 
and diseased subjects to develop a diagnostic tool for these types of diseases.[32]  
However due to the lipophilic nature of all cannabinoids, poor radiographical 
results have been obtained in the presence of fat.  Thus, the design of non-
traditional cannabinoids of the naphthoylindole type, which are less likely to be 
dispersed in fat in vivo, have been pursued.[32]   
Results and Discussion 
The nitrocannabinoid and fluoro authentic sample were synthesized by 
first alkylating the indole, followed by acylation using the Friedel-Crafts reaction.  
4-Nitronaphthoic acid was synthesized by literature procedure.[41]  The 
nitrocannabinoid was dissolved in DMF at a concentration of 10-20 mg/mL and 
loaded onto the microfluidic reactor system. Fluorine-18, kryptofix solution, and 
appropriate anhydrous solvent were also connected.  Discovery runs were 
performed starting at 140 °C and increasing in 20 degree increments.  
Incorporation yields were determined by radio-TLC, and product was verified by 
radio-HPLC coelution with authentic sample.  Radiosynthesis of this molecule 
has been performed under thermal conditions, obtaining a 10% radiochemical 
yield.[32]  Microwave conditions have produced yields of the desired molecule of 





Studies have shown only one enantiomer is normally active towards the 
CB1 receptor,
[32, 42] and although this study has been conducted on a racemic 
mixture, this should not affect the radiochemical yield.  Simple MM2 minimization 
of the enantiomers of the cannabinoid (Figures 19 and 20) was performed with 
Chem3D software using the conformation shown in the work of Willis, et al as a 
starting point.  The active enantiomer has been isolated by chiral resolution, 
however, it is not identified in the literature.  The molecule AM-1220, the 
defluorohydro form of this cannabinoid, is known to be active as the (R)-
enantiomer.   
 
Figure 17. Overlay of THC and non-traditional cannabinoid. 
 
 





Figure 19. (R)-enantiomer of the cannabinoid. 
 
 





Figure 21. MM2 minimized structure of THC as viewed along alcohol O-C bond. 
 
 
Figure 22. (R)-enantiomer as viewed along the ketone O-C bond. 
 






Scheme 8.  Mercury decarboxylation to produce naphthoic acid. 
 
 




Scheme 10.  Friedel-Crafts reaction to produce the cannabinoid. 
 
Materials and Methods 
All chemicals were purchased from Aldrich and used as received.  No-
carrier-added [18F]F-, (740-1110 MBq, specific activity >74 GBq/µmole) produced 
from recycled [18O] water, was obtained from PETNet (Knoxville, TN).  Radio thin 
layer chromatography was performed with radiation detection using a BioScan 
AR-2500 radio-TLC reader and WinScan 1.3 software.  Radio-TLC was 
conducted on C-18 plates employing chloroform as eluent.  Analytical radio-
HPLC analyses were performed on an Agilent 1200 series instrument employing 
a 254 nm UV detector and a Phenomenex C-18 column, 5 µm, 4.6 x 250 mm, 
using a 80:20 mixture of acetonitrile: 0.1 M ammonium formate buffer in a 
standard FBAM gradient.  Prior to microfluidic labeling, the precursor was 
azeotropically dried by addition of 1 mL of acetonitrile and heating until dry three 
times.  Microfluidic fluorine-18 labeling was performed in 100 µm x 2 m reactors 
using the Discovery mode of the Advion NanoTek Microfluidic Synthesis System 
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controlled by NanoTek LF 1.4 Software.    Samples were collected in plastic, 
capped sample vials upon exit from the reactor for analysis.  Vial labeling was 
conducted by adding ~0.5 mL of fluoride solution in DMF to ~0.5 mL 
nitrocannabinoid dissolved in DMF at a concentration of 20 mg/mL.  This solution 
was then heated at 160 °C for ten minutes.  The vial synthesis yielded an 
incorporation of 14%. 
 
2-Chloromethyl-1-methylpiperidine (4) 
Thionyl chloride (5.00 mL; 68.9 mmol) was slowly added to a solution of 1-
methyl-2-piperdine methanol (3) (1.8g; 13.9 mmol) in dichloromethane (25 mL) 
contained in a 100 mL round bottomed flask.  After refluxing overnight, the 
solution was neutralized with saturated sodium bicarbonate solution and then 
extracted with dichloromethane.  The organic layer was dried over anhydrous 
Na2SO4 and solvent removed under reduced pressure to yield product as a light 
brown liquid (1.71 g; 83%) which was used in the next reaction.  
   
 
1-((1-Methylpiperidin-2-yl)methyl)-1H-indole (5) 
Indole (0.61 g; 5.2 mmol) was dissolved in dimethylsulfoxide (13 mL).  Potassium 
hydroxide (2.05 g; 36.5 mmol) was added and the reaction heated to 80 °C for 4 
h.  2-Chloromethyl-1-methylpiperidine was added and the mixture refluxed 
overnight.  After cooling to room temperature, the mixture was poured onto ice 
(50 g).  The mixture was extracted with toluene (3 x 50 mL) and the organic layer 
washed with water and dried over anhydrous Na2SO4.  Solvent was removed and 
product purified by flash chromatography with 10:1 toluene:triethylamine eluent 
to give 0.35 g of brown oil (29.7%).  1H NMR (500 MHz, Chloroform-d) δ 7.60 (dt, 
J = 7.9, 0.9 Hz, 1H), 7.31 (dd, J = 8.3, 0.9 Hz, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.2 
Hz, 1H), 7.07 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.01 (d, J = 3.2 Hz, 1H), 6.46 (dd, J 
= 3.2, 0.8 Hz, 1H), 4.46 (dd, J = 14.2, 4.3 Hz, 1H), 3.81 (dd, J = 14.2, 9.3 Hz, 
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1H), 2.83 (dtd, J = 11.7, 3.5, 1.6 Hz, 1H), 2.40 (s, 3H), 2.33 (dddd, J = 10.3, 9.3, 
4.3, 3.1 Hz, 1H), 2.12 – 2.03 (m, 1H), 1.62 – 1.46 (m, 3H), 1.28 – 0.99 (m, 3H). 
 
4-Nitronaphthoic acid (2) 
4-Nitro-1,8-naphthalic anhydride (1.0 g; 4.1 mmol), water (20 mL), and sodium 
hydroxide (0.544g; 13.6 mmol) were added to a 100 mL round bottomed flask 
and stirred at 80 °C until the solution became clear.  Acetic acid (1.24 mL; 21.6 
mmol), mercury(II) acetate (1.6 g; 5.0 mmol), and a drop of silicone oil were 
added and the mixture refluxed 4 days.  The reaction was judged to be complete 
when a sample was soluble in aqueous NaOH and also did not give mercury 
upon exposure to copper wire.  The solution was filtered to obtain the solid 
organomercury intermediate which was washed with water to remove acetic acid 
and the solid returned to the same flask.  Excess 6 M HCl was added and the 
mixture refluxed for 4 h.  The reaction was cooled to room temperature and 2 
was filtered off as a cream colored solid.   The filtrate produced metallic mercury 
upon exposure to copper wire.  The solid was dried over phosphorous pentoxide 
to give 0.61 g of material.  To purify, the material can be crystallized from glacial 
acetic acid or refluxed with neat thionyl chloride, excess thionyl chloride removed 
by vacuum, and remaining solid treated with excess absolute ethanol.  Excess 
ethanol was removed and the resultant ester purified by flash chromatography 
using 1:1 hexane:ethyl acetate eluent to give 0.35 g of a yellow solid (34.9% 
yield).  Some of the ester (0.1 g) was refluxed overnight in 2 M NaOH and 
neutralized with 6 M HCl to give a brown precipitate which was filtered from the 
solution.  This solid was dissolved in glacial acetic acid and filtered to remove 
salts to give 0.044 g 4-nitronaphthoic acid.  The melting point obtained from the 
product (220-223 °C) was in accord with literature melting points (ranging from 







4-Fluoro-1-naphthoic acid (97 mg; 0.51 mmol) was heated in excess neat thionyl 
chloride until solution was clear. The remaining thionyl chloride was then 
removed using a rotary evaporator and vacuum.  The resulting acid chloride was 
dissolved in ~1 mL of dry methylene chloride, then added to a solution of 
aluminum trichloride (78 mg; 0.59 mmol) in dry methylene chloride (~1 mL) under 
argon purge, to give a bright yellow color immediately upon addition.  This 
solution was then stirred 30 minutes, whereupon it was added to a solution of 1-
((1-methylpiperidin-2-yl)methyl)-1H-indole (5) (51 mg; 0.23 mmol) in dry 
methylene chloride dropwise at room temperature, under argon.  The reaction 
was stirred at room temperature for 4h and then neutralized with 2 N sodium 
hydroxide.  The product was extracted into methylene chloride, washed with 
brine solution, and dried over anhydrous sodium sulfate and then concentrated 
on a rotary evaporator.  Flash chromatography on basic alumina using 6:4:1 
hexane:chloroform:triethylamine yielded 23.7 mg (26%) product.  1H NMR (500 
MHz, Chloroform-d) δ 8.39 – 8.34 (m, 1H), 8.22 – 8.18 (m, 1H), 8.14 – 8.10 (m, 
1H), 7.58 (dd, J = 7.8, 5.4 Hz, 1H), 7.52 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.47 
(ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.36 – 7.26 (m, 4H), 7.13 (dd, J = 10.1, 7.8 Hz, 
1H), 4.46 (dd, J = 14.1, 4.2 Hz, 1H), 3.80 (dd, J = 14.1, 8.9 Hz, 1H), 2.82 – 2.75 
(m, 1H), 2.34 (s, 3H), 2.30 (d, J = 3.8 Hz, 1H), 2.05 (td, J = 11.7, 2.9 Hz, 1H), 




4-Nitronaphthoic acid (40-70 mg) was refluxed in thionyl chloride(~5 mL)  for 2-4 
hours to generate acid chloride.  Excess thionyl chloride was removed using a 
rotary evaporator, leaving a solid yellow-green acid chloride solid.  To this was 
added 1-2 mL of dry methylene chloride to facilitate transfer into the stirred 
aluminum trichloride/methylene chloride solution (50-70 mg in approximately 1 
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mL).  Upon addition under argon purge, a deep red-orange color was 
immediately observed.  This solution was stirred 30 minutes and then added 
dropwise to a stirred solution of the indole moiety 5 in methylene chloride (20-60 
mg in 1-5 mL), under argon.  Various ratios of naphthoic acid to indole moiety 
were tested ranging from 2.4:1 and 1.1:1.  These were stirred for 4 hours, or until 
no indole starting material was visible on TLC.  The reactions were neutralized 
with 2 N NaOH and extracted with methylene chloride.  The organic layer was 
washed with brine solution and evaporated to yield yellow-brown oily solid.  
Purification was effected using activated, basic, Brockmann I aluminum oxide 
with a solvent system consisting of 6:4:1 hexane:chloroform:triethylamine.  The 
product (26.6 mg, 27%) was obtained from a reaction containing 66 mg of 2.  1H 
NMR (500 MHz, Chloroform-d) δ 8.57 – 8.53 (m, 1H), 8.46 – 8.42 (m, 1H), 8.23 
(d, J = 7.7 Hz, 1H), 8.20 (d, J = 9.1 Hz, 1H), 7.74 (ddd, J = 8.5, 6.9, 1.2 Hz, 1H), 
7.68 (d, J = 7.7 Hz, 1H), 7.58 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.45 – 7.37 (m, 3H), 
7.32 (s, 1H), 4.51 (dd, J = 14.1, 4.3 Hz, 1H), 3.87 (dd, J = 14.1, 8.9 Hz, 1H), 2.84 
(d, J = 11.8 Hz, 1H), 2.39 (s, 3H), 2.36 (d, J = 4.5 Hz, 1H), 2.12 (td, J = 11.7, 2.9 
Hz, 1H), 1.66 – 1.42 (m, 3H), 1.33 – 1.05 (m, 3H). 
 
General Procedure for Preparation of [18F]-labeled Cannabinoid 
Nitrocannabinoid 6 (10-20 mg) was dissolved in DMF to create a solution of 10-
20 mg/mL and placed in a 1 mL glass tapered bottom vial and sealed with a 
septum.  [18F]Fluoride was eluted from an MP-1 ion exchange trap with standard 
K2CO3/K222 solution and dried using the NanoTek concentrator module.  
Optimization studies were then conducted starting at 140 °C at a 1:1 P3:P1 ratio 
at a flow rate of 30 µL/min.  Radio-TLC was conducted on C-18 silica plates 








 A non-traditional cannabinoid and known agonist of the CB1 receptor has 
been synthesized and radiolabeled.  A literature vial synthesis has been 
duplicated and radiolabeling has been attempted under microfluidic conditions.  
The radiolabeled cannabinoid product has been produced in the microfluidic 
reactor.  However, attempts at optimization of the microfluidic radiolabeling of the 
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Radio-HPLC of III-5, produced from III-1 coinjection with authentic sample (upper channel 













Radio-HPLC of III-5, produced from III-2 (upper channel radioactivity; lower channel UV/Vis) 
 
Radio-HPLC of III-5, produced from III-2 coinjection with authentic sample (upper channel 














Radio-HPLC of III-5, produced from III-3 (upper channel radioactivity; lower channel UV/Vis) 
 
Radio-HPLC of III-5, produced from III-3 coinjection with authentic sample (upper channel 



















Radio-HPLC of III-5, produced from III-4 (upper channel radioactivity; lower channel UV/Vis) 
 
Radio-HPLC of III-5, produced from III-4 coinjection with authentic sample (upper channel 


































































[18F]FBAMPy radio-HPLC (upper channel radioactivity; lower channel UV/Vis) 
 
[18F]FBAMPy radio-HPLC coinjection with authentic sample (upper channel 














































MS[1];0.483..0.573; / ESI+ / 131008_Kabalka_Moore_401and429 









Mass spectrum of V-7, fluorocannabinoid, DART, positive mode 
MS[1];0.938..0.995; / ESI+ / 131008_Kabalka_Moore_401and429 
































F]V-7, from vial synthesis (upper channel radioactivity; lower channel UV/Vis), 














F]V-7, from precursor-carrier-added microfluidic synthesis (upper channel 
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